Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Eporgen Venture was an Italian seed-capital firm established around 2004-2005, dedicated to the life sciences sector, particularly biotechnology. The firm operated from the Bioindustry Park Silvano Fumero in Colleretto Giacosa, near Turin, and was funded by private, non-institutional investors. Its mission was to finance and build biotech startups, focusing on projects that developed intellectual property to proof-of-concept stage.
During its operational years, Eporgen played a significant role in fostering biotech innovation in Italy. The firm was notable for being the first Italian venture capital company funded entirely by private, non-institutional investors. Although it appears to be inactive now, Eporgen's historical contributions to the biotech landscape in Italy remain significant.
Eporgen Venture specialized in seed capital investments within the life sciences sector, particularly in biotechnology. The firm focused on projects related to oncology, therapeutic vaccines, cardiovascular diseases, anti-infectives, autoimmune diseases, diagnostics, and molecular biology technologies. Its investment strategy revolved around creating independent startups from academic research and managing them through their early development stages.
Eporgen aimed to identify life-sciences intellectual property from academic research, fund these projects through proof-of-concept, and seek licensing or partnering opportunities with larger pharmaceutical companies. The check sizes for investments typically ranged from $250,000 to $600,000, allowing the firm to support multiple startups simultaneously.
Eporgen Venture's portfolio included several notable companies, particularly in the biotech sector:
Konstantinos Efthymiopoulos: President of Eporgen Venture, associated with the firm in 2012 and recognized for his leadership in the biotech investment space.
Silvano Fumero: Founder and former president of Eporgen Venture, credited with establishing the firm's focus on biotech seed capital.
Gianni Garotta: Scientific Director, listed as a key figure in the firm around 2012, contributing expertise in the life sciences sector.
As of now, Eporgen Venture appears to be inactive, with no recent investments or updates reported. The last notable activity was the sale of Genovax's global rights to Mediolanum Farmaceutici in 2012, marking a significant exit for the firm.
Independent research indicates that the firm has not engaged in any new investments since its operational peak, and its website is currently inactive, suggesting a likely defunct status.
What are Eporgen Venture's investment criteria?
Eporgen Venture focuses on seed capital investments in the life sciences sector, particularly in biotechnology. They look for projects that can develop intellectual property to proof-of-concept stage, especially in areas like oncology and therapeutic vaccines.
How can I pitch to Eporgen Venture?
While Eporgen Venture is currently inactive, historically, they preferred to engage with startups that have a clear path to proof-of-concept and potential for licensing or partnerships with larger pharmaceutical companies.
What makes Eporgen Venture different from other investors?
Eporgen Venture was notable for being the first Italian venture capital firm funded entirely by private, non-institutional investors, which allowed them to focus specifically on the biotech sector without institutional constraints.
What is the geographic focus of Eporgen Venture?
Eporgen Venture primarily focused on investments within Italy, particularly in the Piedmont region, where it was based.
What is the typical check size for investments?
Eporgen Venture typically invested between $250,000 and $600,000 in each startup, allowing them to support multiple projects simultaneously.
What kind of support does Eporgen Venture provide to its portfolio companies?
Eporgen Venture provided centralized management and support to its portfolio companies, helping them navigate the biotech landscape and facilitating partnerships with larger pharmaceutical companies for licensing and exit opportunities.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.